This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

BioPharm America
BioPharm America is merging with LSX USA
Hynes Convention Center | Boston, MA

September 11–12, 2024

Chris Learn
Vice President, Cell and Gene Therapy at Parexel


20+ years of trial execution and team management experience. Team leader in the registrational development, agency submission and regulatory approval of Imbruvica®, Yondelis® and Keytruda®, as well as Yescarta® clinical development, following initial market authorization. Also oversaw the outsourced global trialing operations for the clinical development of CAR-T assets Lisocabtagene Maraleucel (liso-cel) and Idecabtagene Vicleucel (ide-cel) currently under BLA review at FDA.
Previously Senior Director, Clinical Development at Istari Oncology, Senior Director Cell & Gene Therapy Center of Excellence at IQVIA, and Program Manager Oncology/Hematology at ICON
Wake Forest University, Doctor of Philosophy, Microbiology and Immunology; Virginia Tech, Biology, Chemistry

Agenda Sessions

  • CGT development and commercialization


At this event